These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21724122)

  • 1. Magnetic resonance spectroscopic imaging of benign prostatic tissue: findings at 3.0 T compared to 1.5 T-initial experience.
    Chitkara M; Westphalen A; Kurhanewicz J; Qayyum A; Poder L; Reed G; Coakley FV
    Clin Imaging; 2011; 35(4):288-93. PubMed ID: 21724122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D MR-spectroscopic imaging assessment of metabolic activity in the prostate during the PSA "bounce" following 125iodine brachytherapy.
    Kirilova A; Damyanovich A; Crook J; Jezioranski J; Wallace K; Pintilie M
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):371-8. PubMed ID: 20421147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines.
    Shukla-Dave A; Hricak H; Moskowitz C; Ishill N; Akin O; Kuroiwa K; Spector J; Kumar M; Reuter VE; Koutcher JA; Zakian KL
    Radiology; 2007 Nov; 245(2):499-506. PubMed ID: 17890357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology.
    García-Segura JM; Sánchez-Chapado M; Ibarburen C; Viaño J; Angulo JC; González J; Rodríguez-Vallejo JM
    Magn Reson Imaging; 1999 Jun; 17(5):755-65. PubMed ID: 10372529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging.
    Kurhanewicz J; Vigneron DB; Hricak H; Parivar F; Nelson SJ; Shinohara K; Carroll PR
    Radiology; 1996 Aug; 200(2):489-96. PubMed ID: 8685346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate MRI and 3D MR spectroscopy: how we do it.
    Verma S; Rajesh A; Fütterer JJ; Turkbey B; Scheenen TW; Pang Y; Choyke PL; Kurhanewicz J
    AJR Am J Roentgenol; 2010 Jun; 194(6):1414-26. PubMed ID: 20489079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings.
    Aydin H; Kizilgöz V; Tatar IG; Damar C; Ugan AR; Paker I; Hekimoğlu B
    J Comput Assist Tomogr; 2012; 36(1):30-45. PubMed ID: 22261768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technical Note: evaluation of the uncertainties in (choline + creatine)/citrate ratios measured by proton MR spectroscopic imaging in patients suspicious for prostate cancer.
    Zbýň Š; Krššák M; Memarsadeghi M; Gholami B; Haitel A; Weber M; Helbich TH; Trattnig S; Moser E; Gruber S
    Rofo; 2014 Jul; 186(7):698-702. PubMed ID: 24940925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of Histopathologic Tissue Composition to Quantitative MR Spectroscopy and Diffusion-weighted Imaging of the Prostate.
    Kobus T; van der Laak JA; Maas MC; Hambrock T; Bruggink CC; Hulsbergen-van de Kaa CA; Scheenen TW; Heerschap A
    Radiology; 2016 Mar; 278(3):801-11. PubMed ID: 26418614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features--initial experience.
    Hom JJ; Coakley FV; Simko JP; Lu Y; Qayyum A; Westphalen AC; Schmitt LD; Carroll PR; Kurhanewicz J
    Radiology; 2007 Feb; 242(2):483-9. PubMed ID: 17179396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of prostate cancer with MR spectroscopic imaging and diffusion-weighted imaging at 3 Tesla.
    Mazaheri Y; Shukla-Dave A; Goldman DA; Moskowitz CS; Takeda T; Reuter VE; Akin O; Hricak H
    Magn Reson Imaging; 2019 Jan; 55():93-102. PubMed ID: 30176373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution.
    Kurhanewicz J; Vigneron DB; Hricak H; Narayan P; Carroll P; Nelson SJ
    Radiology; 1996 Mar; 198(3):795-805. PubMed ID: 8628874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging--initial results.
    Zakian KL; Eberhardt S; Hricak H; Shukla-Dave A; Kleinman S; Muruganandham M; Sircar K; Kattan MW; Reuter VE; Scardino PT; Koutcher JA
    Radiology; 2003 Oct; 229(1):241-7. PubMed ID: 12920178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings.
    Mazaheri Y; Shukla-Dave A; Hricak H; Fine SW; Zhang J; Inurrigarro G; Moskowitz CS; Ishill NM; Reuter VE; Touijer K; Zakian KL; Koutcher JA
    Radiology; 2008 Feb; 246(2):480-8. PubMed ID: 18227542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everyman's prostate phantom: kiwi-fruit substitute for human prostates at magnetic resonance imaging, diffusion-weighted imaging and magnetic resonance spectroscopy.
    Mueller-Lisse UG; Murer S; Mueller-Lisse UL; Kuhn M; Scheidler J; Scherr M
    Eur Radiol; 2017 Aug; 27(8):3362-3371. PubMed ID: 28058480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MR spectroscopy as a reliable diagnostic tool for localization of prostate cancer.
    Hasumi M; Suzuki K; Oya N; Ito K; Kurokawa K; Fukabori Y; Yamanaka H
    Anticancer Res; 2002; 22(2B):1205-8. PubMed ID: 12168926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compressive sensing could accelerate 1H MR metabolic imaging in the clinic.
    Geethanath S; Baek HM; Ganji SK; Ding Y; Maher EA; Sims RD; Choi C; Lewis MA; Kodibagkar VD
    Radiology; 2012 Mar; 262(3):985-94. PubMed ID: 22357898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined morphological, [1H]-MR spectroscopic and contrast-enhanced imaging of human prostate cancer with a 3-Tesla scanner: preliminary experience.
    Carlani M; Mancino S; Bonanno E; Finazzi Agrò E; Simonetti G
    Radiol Med; 2008 Aug; 113(5):670-88. PubMed ID: 18493829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging.
    Westphalen AC; Coakley FV; Qayyum A; Swanson M; Simko JP; Lu Y; Zhao S; Carroll PR; Yeh BM; Kurhanewicz J
    Radiology; 2008 Jan; 246(1):177-84. PubMed ID: 18024434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility.
    Scheenen TW; Heijmink SW; Roell SA; Hulsbergen-Van de Kaa CA; Knipscheer BC; Witjes JA; Barentsz JO; Heerschap A
    Radiology; 2007 Nov; 245(2):507-16. PubMed ID: 17848681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.